The use of long-acting somatostatin analogues in acromegaly

Growth Hormone and IGF Research

Volumn 10, Issue SUPPL. B, 2000, Pages

  Jenkins, P J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Lanreotide; Octreotide LAR

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ACROMEGALY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FLATULENCE; HORMONE RELEASE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; STEATORRHEA; TREATMENT OUTCOME;

EID: 0033903207     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(00)80021-0     Document Type: Article

References (10)

1. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group
2. Results of a European multicentre study with Sandostatin LAR in acromegalic patients
3. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
4. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
5. Sandostatin LAR in acromegalic patients: Long-term treatment
6. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
7. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
8. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study
9. A comparison of lanreotide and octreotide LAR for treatment of a cromegaly
10. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide